单位:[1]Department of Cardiology, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.[2]Department of Cardiology, Beijing Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.[3]Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.[4]Department of Cardiology, Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China.[5]Department of Cardiology, China-Japan Friendship Hospital, Beijing, China.[6]Department of Cardiology, Anzhen Hospital Affiliated to Capital Medical University, Beijing, China.首都医科大学附属安贞医院
Key Scientific Research
Project of Colleges and Universities in Henan Province
(20A320071), the Capital Health Research and Development
of Special Fund (2022-2-4065), and the National High-Level
Hospital Clinical Research Funding (2022-NHLHCRF-PY-19).
第一作者单位:[1]Department of Cardiology, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
通讯作者:
通讯机构:[1]Department of Cardiology, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.[4]Department of Cardiology, Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China.[5]Department of Cardiology, China-Japan Friendship Hospital, Beijing, China.
推荐引用方式(GB/T 7714):
Wang Zhe,Wang Yijia,Luo Fangyuan,et al.Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients[J].Frontiers In Cardiovascular Medicine.2022,9:960259.doi:10.3389/fcvm.2022.960259.
APA:
Wang Zhe,Wang Yijia,Luo Fangyuan,Zhai Yafei,Li Jiaju...&Sun Yihong.(2022).Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients.Frontiers In Cardiovascular Medicine,9,
MLA:
Wang Zhe,et al."Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients".Frontiers In Cardiovascular Medicine 9.(2022):960259